Survivors of childhood, adolescent, and young adult cancer, previously treated with
anthracycline chemotherapy (including mitoxantrone) or radiotherapy in which the heart was …

Survivors of childhood cancer treated with anthracycline chemotherapy or chest radiation
are at an increased risk of developing congestive heart failure. In this population, congestive …

Cardiac diseases in the growing population of childhood cancer survivors are of major
concern. Cardiotoxicity as a consequence of anthracyclines and chest radiotherapy …

Purpose In pediatric relapsed acute myeloid leukemia (AML), optimal reinduction therapy is
unknown. Studies suggest that liposomal daunorubicin (DNX; DaunoXome; Galen …

Purpose Late cardiotoxicity after pediatric acute myeloid leukemia therapy causes
substantial morbidity and mortality. The impact of early-onset cardiotoxicity on treatment …

Investigations of long‐term outcomes have been instrumental in designing safer and more
effective contemporary therapies for pediatric hematological malignancies. Despite the …

Anthracyclines are chemotherapeutic drugs widely used in the frontline of cancer treatment.
The therapeutic mechanisms involve the stabilization of topoisomerase IIα, DNA, and the …

Background Cardiotoxicity is among the most important adverse effects of childhood cancer
treatment. Anthracyclines, mitoxantrone and radiotherapy involving the heart are its main …

The last decades have seen parallel improvements in chemotherapy‐based and
haematopoietic stem cell transplantation (HSCT) regimens for acute myeloid leukaemia …

PURPOSE To identify effective and less toxic therapy for children with acute myeloid
leukemia, we introduced clofarabine into the first course of remission induction to reduce …